SCHEMBL615411

SCHEMBL615411

C=COC(C)(C)C(C)(C)O.OBO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27905888 0.92
SCHEMBL28879137 0.90
Boric Acid SCHEMBL27984514 0.85
SCHEMBL28377922 0.74 TDP1 (0.30)
Vinyl Ether SCHEMBL404762 0.74
SCHEMBL2985393 0.70
SCHEMBL9724411 0.69
SCHEMBL8663764 0.69
SCHEMBL30987023 0.69
SCHEMBL75200 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250333400-A1 CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-30 US disclosed
US-20240368140-A1 CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-11-07 US disclosed
US-11926619-B2 Certain pladienolide compounds and methods of use EISAI R & D MANAGEMENT CO., LTD. (JP) 2024-03-12 US disclosed
CN-114651000-A Biocatalytic synthesis of nostoc anticancer agents 密歇根大学董事会 2022-06-21 CN disclosed
WO-2022052926-A1 AROMATIC ETHYLENE COMPOUND AND PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF 广州再极医药科技有限公司 2022-03-17 WO disclosed
CN-113166091-A Pladienolide compounds and uses thereof 卫材R&D管理有限公司 2021-07-23 CN disclosed
US-20210163456-A1 CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-06-03 US disclosed
CN-107922349-B Vinyl compounds as FGFR and VEGFR inhibitors 哈尔滨珍宝制药有限公司 2021-05-07 CN disclosed
EP-3774759-A2 PLADIENOLIDE COMPOUNDS AND THEIR USE Eisai R&D Management Co., Ltd. (JP) 2021-02-17 EP disclosed
WO-2019199667-A2 CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE KEANEY GREGG F (US) 2019-10-17 WO disclosed
WO-2014164596-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 WO disclosed
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-11 US disclosed
EP-2537845-B1 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2014-03-19 EP disclosed
EP-2537845-A1 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists Eli Lilly and Company (US) 2012-12-26 EP disclosed
EP-2235007-B1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2012-10-31 EP disclosed
US-20120041193-A1 SUBSTITUTED INTERNAL VINYL-BORONIC ACIDS AND BORONIC ACID DERIVATIVES FRONTIER SCIENTIFIC, INC. (US) 2012-02-16 US disclosed
US-7994164-B2 Mineralocorticoid receptor antagonists and methods of use ELI LILLY AND COMPANY (US) 2011-08-09 US disclosed
EP-2235007-A1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2010-10-06 EP disclosed
WO-2009085584-A1 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2009-07-09 WO disclosed
US-20090163472-A1 MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE ELI LILLY AND COMPANY 2009-06-25 US disclosed